Health Catalyst , Inc.'s (NASDAQ:HCAT) Chief People Officer, Linda Llewelyn, has sold a portion of her company shares, according to the latest regulatory filings. The transaction, which took place on March 15, 2024, involved the sale of 2,005 shares at a price of $7.8043 per share, totaling approximately $15,647.
The sale was executed under a pre-arranged trading plan, known as a 10b5-1 plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. Such plans are set up in advance at a time when the insider does not possess any confidential information that could affect the stock price.
Following the transaction, Llewelyn retains ownership of 128,231 Health Catalyst shares, indicating a continued investment in the company's future. The transaction details, including the number of shares sold and the price per share, were made public through a Form 4 filing with the Securities and Exchange Commission.
Health Catalyst, based in Salt Lake City, Utah, specializes in data and analytics technology for healthcare organizations. The company's stock trades under the ticker HCAT on the NASDAQ. As with all insider transactions, investors often watch these sales closely for insights into executives' perspectives on the company's valuation and prospects.
It's worth noting that insider sales can occur for various reasons, such as diversifying personal financial portfolios or funding personal expenses, and may not necessarily reflect the executive's outlook on the company's future performance.
InvestingPro Insights
As Health Catalyst, Inc. (NASDAQ:HCAT) navigates through the complexities of the healthcare data and analytics sector, its financial metrics and analyst expectations provide a deeper understanding of its current standing and future prospects. With a market capitalization of approximately $463.82 million and a negative P/E ratio of -3.77, investors are keenly observing the company's performance indicators.
An important metric for investors to consider is the company's revenue growth, which stands at 7.13% for the last twelve months as of Q4 2023. This is complemented by a quarterly revenue growth of 8.56% for Q4 2023, signaling a positive trend in the company's top-line performance. Despite these growth figures, Health Catalyst has reported an operating income margin of -29.38% and a return on assets of -16.25% for the same period, highlighting areas where the company may need to improve efficiency and asset utilization.
InvestingPro Tips suggest that Health Catalyst holds more cash than debt on its balance sheet and that analysts have revised their earnings upwards for the upcoming period, indicating a potential upside in future financial results. Additionally, while the company has not been profitable over the last twelve months, analysts predict that Health Catalyst will achieve profitability this year.
Investors interested in a comprehensive analysis and more InvestingPro Tips can explore https://www.investing.com/pro/HCAT for further insights. Currently, there are 5 additional tips listed on InvestingPro that could offer valuable perspectives on Health Catalyst's financial health and stock performance. To dive deeper into these insights, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a more informed investment decision-making process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.